Pulmonx Corporation
Clinical trials sponsored by Pulmonx Corporation, explained in plain language.
Pulmonx Corporation
LUNG
NASDAQ
Develops minimally invasive treatments for chronic obstructive pulmonary disease.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- One-Way valves in the lung: can they help emphysema patients breathe easier? Results expected Dec 2026 (estimated)
- Tiny One-Way valves for emphysema under close watch in japan Results expected Mar 2027 (estimated)
- Foam plug could open door to lung valve therapy for thousands Results expected Jun 2027 (estimated)